Immunosuppression by breast cancer associated p43-effect of immunomodulators.
It has been previously shown that p43- a breast cancer associated antigen-has immunosuppressive properties. The present study was carried out in order to elucidate the pathomechanisms of immunosuppression in breast cancer patients influenced by the expression of p43. Lymphocytes were cultured from blood of 29 women with benign lesions in the breast as well as from 41 female patients with breast cancer. Lymphocyte stimulation was performed by addition of Concanavalin (Con A) in cultures with lymphocytes alone (CONLYM) or in lymphocytes incubated with p43 (CONAg). In other series immunomodulation was tried by addition of indomethacin (INDLYM, INDAg), levamisole (LEVLYM, LEVAg), or interleukin-2 (ILLYM, ILAG). In breast cancer patients, addition of p43 significantly inhibited the activation of lymphocyte proliferation by Con A compared to women with benign tumors. The addition of indomethacin or levamisole did not influence this inhibitory effect of p43 in breast cancer patients. Contrary to these observations, addition of IL-2 resulted in increased proliferation of lymphocytes from patients with benign as well as malignant tumors, which was inhibited after addition of p43. Analysis of the correlation of the immunosuppressive properties of p43 in correlation with prognostic factors for breast cancer showed evidence for a stronger activity of p43 in early stage tumors (i.e. smaller than 2 cm, lymph node negative, histologic grading GI), confirming previous observations of a higher expression of p43 in early stages of breast cancer.
Rosen
H R
HR
Ludwig Boltzmann Research Institute for Surgical Oncology, Vienna, Austria.
Ausch
C
C
Reiner
G
G
Reinerova
M
M
Svec
J
J
Tüchler
H
H
Schiessel
R
R
Moroz
C
C
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000494:pharmacology; D001943:Breast Neoplasms / Q000276:immunology*; D003208:Concanavalin A / Q000494:pharmacology; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D024101:Mitochondrial Proteins; D010444:Peptide Elongation Factor Tu / Q000276:immunology* / Q000494:pharmacology; D013268:Stimulation, Chemical
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D024101:Mitochondrial Proteins; C091648:TUFM protein, human; D003208:Concanavalin A; D010444:Peptide Elongation Factor Tu